Calcitonin Gene-Related Peptide Targeting Therapies for Migraine

September 1, 2019

Two randomized clinical trials showed that calcitonin gene-related peptide targeting therapies are effective and safe for primary headache disorders.

Issue Date: September 1, 2019

Table of Contents

Antisense Oligonucleotide Treatment of Huntington’s Disease: A Novel Potential Treatment
Calcitonin Gene-Related Peptide Targeting Therapies for Migraine
Targeting Fyn Kinase in Alzheimer’s Disease: Another Failed Clinical Trial
Risk of Neuropathy With Fluoroquinolones
Racial and Ethnic Disparities in Thrombectomy in the United States
After Ischemic Stroke Related to Atrial Fibrillation, Direct Oral Anticoagulants Are Superior to Vitamin K Antagonists
Faster Time to Endovascular Reperfusion Therapy Results in Better Outcomes

Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Editorial Group Manager Leslie Coplin; Editor Jason Schneider; and Accreditations Manager Amy M. Johnson, MSN, RN, CPN, report no financial relationships relevant to this field of study.

Shop Now: Search Products

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements

Emergency
Hospital
Clinical
All Access
Help
Search
About Us
Newsletters
FreeCME

The trusted source for healthcare information and CONTINUING EDUCATION.

ACCOUNTS RECEIVABLE

AR@relias.com

MAILING ADDRESS

1010 Sync St., Suite 100

Morrisville, NC 27560-5468

USA

Do Not Sell My Personal Information
Privacy Policy
Terms Of Use
Help
Group Sales

For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

We use cookies to create a better experience. By continuing to use our site, you consent to the use of cookies outlined in our Privacy Policy.

Close Banner